Kinetic studies on 2',2'-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase

Biochemical Pharmacology

Volumn 45, Issue 9, 1993, Pages 1857-1861

  Bouffard, David Y ^a   Laliberté, Josée ^a   Momparler, Richard L ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DIAZEPINONE RIBOSIDE; ENZYME INHIBITOR; GEMCITABINE; RADIOISOTOPE; TETRAHYDROURIDINE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DEAMINATION; DRUG METABOLISM; ENZYME KINETICS; ENZYME PURIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PHOSPHORYLATION; PLACENTA; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; AZEPINES; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DEOXYCYTOSINE NUCLEOTIDES; HALF-LIFE; HUMAN; KINETICS; SUPPORT, NON-U.S. GOV'T; TETRAHYDROURIDINE;

EID: 0027197028     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(93)90444-2     Document Type: Article

References (30)

1. Synthesis of 2-deoxy-2,2-difluoro-d-ribose and 2-deoxy-2,2-dinuoro-d-ribofuranosyl nucleosides
2. Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer
3. Pharmacokinetics of Gemcitabine (LY 188011; difluo-rodeoxycytidine) administered every two weeks in a Phase I study
4. Evaluation of the antitumor activity of Gemcitabine (2',2'-difluoro-deoxycytidine)
5. A phase II study of Gemcitabine in non-small cell lung cancer (NSCLC) using a twice weekly schedule
6. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
7. 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase
8. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine
9. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: A mechanism of self-potentiation
10. Action of 2',2'-difluorodeoxycytidine on DNA synthesis
11. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-β-d-arabinofuranosylcytosine
12. 2',2'-Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells
13. Purification and properties of cytidine deaminase from normal and leukemic granulocytes
14. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase
15. Metabolism and action of 2',2'-difluorodeoxycytidine in human leukemic cells
16. Distribution of kinase and deaminase of 1-β-d-arabinofuranosylcytosine in tissues of man and mouse
17. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-aza-2'-deoxycytidine
18. Cytidine deaminase and the development of resistance to cytosine arabinoside
19. Studies of the enzymatic deamination of aracytidine: V. Inhibition in vitro and in vivo by tetrahydrouridine and other related pyrimidine nucleosides
20. Effect of tetrahydrouridine on the clinical pharmacology of 1-β-d-arabinofuranosylcytosine when both drugs are coinfused over three hours
21. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase
22. Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase
23. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
24. Human T-lymphoblast deoxycytidine kinase:Purification and properties
25. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides
26. Comparison of the antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against humanmyeloid and lymphoid leukemic cells
27. Cellular pharmacology of 1-β-d-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells
28. Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)—A pilot study
29. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
30. Gemcitabine in leukemia A phase I clinical plasma and cellular pharmacology study